Article Sidebar

PDF
Date Published: 04/10/2025
Abstract Views: 2
Views PDF: 1
DOI: https://doi.org/10.56535/jmpm.v50si2.1592
Issue
Vol. 50 No. si2 (2025): TẠP CHÍ Y DƯỢC HỌC QUÂN SỰ - SỐ ĐẶC BIỆT 10/2025
Section
Hội nghị Khoa học lần thứ XI - VUNA-North
How to Cite
Do, D. V. (2025). EVALUATION OF OVERACTIVE BLADDER TREATMENT OUTCOMES IN POST-STROKE PATIENTS USING MIRABEGRON (BETA-3 AGONIST) AT BACH MAI HOSPITAL. Journal of Military Pharmaco-medicine, 50(si2), 48-56. https://doi.org/10.56535/jmpm.v50si2.1592

EVALUATION OF OVERACTIVE BLADDER TREATMENT OUTCOMES IN POST-STROKE PATIENTS USING MIRABEGRON (BETA-3 AGONIST) AT BACH MAI HOSPITAL

Dao Vu Do1,2,3,
1 Bệnh viện Bạch Mai
2 Đại học Y tế Công cộng
3 Đại học Y Dược, Đại học Quốc Gia Hà Nội

Main Article Content

Abstract

Objectives: To evaluate the treatment outcomes of overactive bladder (OAB) in post-stroke patients using Mirabegron and related factors. Methods: A cross-sectional descriptive study without a control group was conducted on 30 patients diagnosed with post-stroke OAB at Bach Mai Hospital from October 2024 to June 2025. OAB symptoms were assessed using the OAB Symptom Score (OABSS), quality of life was measured with the International Prostate Symptom Score - Quality of Life, and voiding patterns were recorded through a urinary diary. Results: The results showed significant improvement in OAB symptoms (the OAB Symptom Score decreased from 10.97 to 5.7) and quality of life (International Prostate Symptom Score - Quality of Life decreased from 5.51 to 3.17). The frequency of urination, nocturia, urgency, and urinary incontinence significantly decreased (p < 0.05), as reflected in the voiding diary data. Mild side effects such as increased blood pressure and tachycardia were recorded, but did not require discontinuation of treatment. Factors such as age and the type of stroke influenced treatment outcomes. Conclusion: Mirabegron is an effective and safe option for managing OAB in post-stroke patients.

Article Details

Keywords

Overactive Bladder, Stroke, Mirabegron

References

1. Pyo H, Kim BR, Park M, Hong JH, Kim EJ. Effects of overactive bladder symptoms in stroke patients’ health-related quality of life and their performance scale. Ann Rehabil Med. 2017 Dec 28; 41(6):935-943.
2. Agapiou E, Pyrgelis ES, Mavridis IN, Meliou M, Wimalachandra WSB. Bladder dysfunction following stroke: An updated review on diagnosis and management. Bladder (San Franc). 2024 Aug 23; 11(1):e21200005.
3. Szabo SM, Gooch KL, Walker DR, Johnston KM, Wagg AS. The association between overactive bladder and falls and fractures: A systematic review. Adv Ther. 2018; 35(11):1831-1841.
4. Chapple CR, Cruz F, Cardozo L, Staskin D, Herschorn S, Choudhury N, et al. Safety and efficacy of mirabegron: Analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo. Eur Urol. 2020 Jan; 77(1):119-128.
5. O’Kane M, Robinson D, Cardozo L, Wagg A, Abrams P. Mirabegron in the management of overactive bladder syndrome. Int J Womens Health. 2022 Sep 16; 14:1337-1350.
6. Winstein CJ, Stein J, Arena R, Bates B, Cherney LR, Cramer SC, et al. Guidelines for adult stroke rehabilitation and recovery: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016 Jun; 47(6):e98-169.
7. ICS [Internet]. ICS terminology [Overactive Bladder]. [cited 2025 Aug 5]. Available from: https://www.ics.org/ terminology/23.
8. Vasudeva P, Kumar A, Yadav S, Kumar N, Chaudhry N, Prasad V, et al. Neurological safety and efficacy of darifenacin and mirabegron for the treatment of overactive bladder in patients with history of cerebrovascular accident: A prospective study. Neurourol Urodyn. 2021 Nov; 40(8):2041-2047.
9. Sato H, Otsuka S, Tsukada S. Mirabegron versus vibegron in previously untreated female patients with overactive bladder: A randomized, single-clinic, open-label trial. LUTS: Lower Urinary Tract Symptoms. 2023; 15(4):129-138.
10. Ito H, Matsuo T, Mitsunari K, Ohba K, Miyata Y. Impact of mirabegron administration on the blood pressure and pulse rate in patients with overactive bladder. Medicina (Kaunas). 2022 Jun 19; 58(6):825.